Blake Hand
Nurse Practitioner · Gardendale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Gardendale Pain and Wellness LLC · Family First Urgent Care Alabama LLC
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Blake Hand’s office to ask if they take your plan before you enroll.
Original Medicare doctor bills
$11,562
Medicare paid this office $11,562 for 93 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 61 | $5,510 | $61 |
| Short return visit (20+ min) | 30 | $1,813 | $55 |
| Testing for presence of drug, by chemistry analyzers | 29 | $1,766 | $59 |
| Assessment of emotional or behavioral problems | 63 | $215 | $3 |
| Injection of drug or substance under skin or into muscle | 18 | $195 | $5 |
See all 6 services
| Return visit (30+ min) | 61 | $5,510 | $61 |
| Short return visit (20+ min) | 30 | $1,813 | $55 |
| Testing for presence of drug, by chemistry analyzers | 29 | $1,766 | $59 |
| Assessment of emotional or behavioral problems | 63 | $215 | $3 |
| Injection of drug or substance under skin or into muscle | 18 | $195 | $5 |
| Insertion of needle into vein for collection of blood sample | 14 | $147 | $9 |
Who their Medicare patients are
93 Original Medicare patients in 2024. Average age 69 · Women 67% · Also on Medicaid 13% · Health risk score 1.35. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Depression 41% · Diabetes 35% · Coronary heart disease 26% · Heart failure 26% · Chronic kidney disease 26% · COPD 26%.
The office billed $26,166, Medicare allowed $15,779 and paid $11,562; for 2,444 services of 28 kinds; $70 of it was for drugs given in the office and $11,492 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 93 | 2,444 | 69 | 1.35 | $26,166 | $11,562 |
| 2023 | 69 | 2,782 | 67 | 0.91 | $27,869 | $13,555 |
| 2022 | 44 | 1,900 | 69 | 0.97 | $8,804 | $4,834 |
| 2021 | 27 | 1,410 | 70 | 0.77 | $5,759 | $3,149 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 49 | $7,518 | $69 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $1,317 | $101 |
| Detection test by immunoassay with direct visual observation for influenza virus | 17 | $616 | $16 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 15 | $589 | $35 |
| Injection of drug or substance under skin or into muscle | 45 | $570 | $6 |
| Insertion of needle into vein for collection of blood sample | 34 | $349 | $6 |
| Hemoglobin a1c level | 12 | $164 | $9 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 15 | $163 | None |
| Injection, ceftriaxone sodium, per 250 mg | 16 | $20 | None |
| Injection, ketorolac tromethamine, per 15 mg | 12 | $13 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 28 | $12 | None |
2022: 6 services
| Return visit (30+ min) | 26 | $2,063 | $76 |
| Short return visit (20+ min) | 11 | $624 | $52 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 16 | $591 | $35 |
| Injection of drug or substance under skin or into muscle | 21 | $247 | $7 |
| Insertion of needle into vein for collection of blood sample | 11 | $33 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 15 | $9 | None |
2021: 3 services
| Return visit (30+ min) | 20 | $1,932 | $81 |
| Injection of drug or substance under skin or into muscle | 19 | $218 | $7 |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $7 | None |
Medicaid work
$1,198 in 2024
Medicaid paid $1,198 for 20 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 20 | $1,198 |
| 2024 | 20 | 1 | 17 | $1,198 |
| 2023 | 306 | 7 | 22 | $13,403 |
| 2022 | 54 | 3 | 13 | $1,538 |
| 2021 | 24 | 1 | 24 | $633 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 165 | $10,519 |
| SARSCOV CORONAVIRUS AG IA | 53 | $1,213 |
| New patient visit (30+ min) | 15 | $922 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 31 | $336 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 14 | $264 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 15 | $140 |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $9 |
2022
| New patient visit (30+ min) | 15 | $619 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 25 | $550 |
| SARSCOV CORONAVIRUS AG IA | 14 | $369 |
2021
| SARSCOV CORONAVIRUS AG IA | 24 | $633 |
Drugs they prescribed that Part D paid
$96,627
Pharmacies billed $96,627 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 12% of their Part D prescriptions (147 of 1,264) in 2024. A higher opioid share than 9 in 10 peers; the typical nurse practitioner clinician is at 0%.
1,127 generic and fewer than 11 brand-name prescriptions · $96,627 in drug cost · 40 antibiotic prescriptions to 26 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mounjaro | 18 | $17,294 | $961 |
| Buprenorphine-Naloxone | 15 | $2,526 | $168 |
| Fluticasone-Salmeterol | 15 | $2,312 | $154 |
| Hydrocodone-Acetaminophen | 73 | $1,910 | $26 |
| Oxycodone-Acetaminophen | 64 | $1,501 | $23 |
See all 33 drugs
| Mounjaro | 18 | $17,294 | $961 |
| Buprenorphine-Naloxone | 15 | $2,526 | $168 |
| Fluticasone-Salmeterol | 15 | $2,312 | $154 |
| Hydrocodone-Acetaminophen | 73 | $1,910 | $26 |
| Oxycodone-Acetaminophen | 64 | $1,501 | $23 |
| Mirtazapine | 13 | $754 | $58 |
| Gabapentin | 53 | $751 | $14 |
| Atorvastatin | 44 | $701 | $16 |
| Pregabalin | 29 | $695 | $24 |
| Lisinopril | 36 | $541 | $15 |
| Tizanidine | 48 | $487 | $10 |
| Levothyroxine | 30 | $438 | $15 |
| Cyclobenzaprine | 36 | $426 | $12 |
| Albuterol Sulfate Hfa | 18 | $398 | $22 |
| Ondansetron Odt | 12 | $370 | $31 |
| Omeprazole | 17 | $315 | $19 |
| Olmesartan Medoxomil | 19 | $262 | $14 |
| Amlodipine Besylate | 26 | $252 | $10 |
| Metoprolol | 17 | $249 | $15 |
| Celecoxib | 18 | $240 | $13 |
| Montelukast | 16 | $228 | $14 |
| Fluticasone Propionate | 12 | $228 | $19 |
| Methocarbamol | 25 | $227 | $9 |
| Pravastatin | 13 | $183 | $14 |
| Pantoprazole | 20 | $175 | $9 |
| Losartan | 15 | $162 | $11 |
| Metformin | 20 | $130 | $6 |
| Doxycycline Hyclate | 11 | $121 | $11 |
| Hydrochlorothiazide | 20 | $110 | $6 |
| Sertraline | 15 | $110 | $7 |
| Rosuvastatin | 13 | $76 | $6 |
| Meloxicam | 18 | $33 | $2 |
| Prednisone | 15 | $16 | $1 |
Year by year
| 2024 | 1,264 | 300 | 12% (147) | None | $96,627 |
| 2023 | 976 | 134 | None | None | $104,136 |
| 2022 | 430 | 118 | 0% (0) | None | $33,804 |
| 2021 | 359 | 123 | 0% (0) | 16% | $30,179 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Mounjaro | 14 | $17,817 | $1,273 |
| Trelegy Ellipta | 12 | $8,370 | $697 |
| Atorvastatin | 43 | $827 | $19 |
| Albuterol Sulfate Hfa | 31 | $789 | $25 |
| Pantoprazole | 38 | $607 | $16 |
| Levothyroxine | 34 | $597 | $18 |
| Omeprazole | 17 | $424 | $25 |
| Losartan | 19 | $392 | $21 |
| Cefdinir | 13 | $365 | $28 |
| Fluticasone Propionate | 20 | $353 | $18 |
| Olmesartan Medoxomil | 20 | $326 | $16 |
| Trazodone | 15 | $309 | $21 |
| Promethazine | 22 | $298 | $14 |
| Montelukast | 11 | $288 | $26 |
| Lisinopril | 30 | $284 | $9 |
| Doxycycline Hyclate | 11 | $272 | $25 |
| Cyclobenzaprine | 18 | $272 | $15 |
| Amlodipine Besylate | 28 | $264 | $9 |
| Sertraline | 21 | $195 | $9 |
| Simvastatin | 11 | $192 | $17 |
| Metformin | 25 | $191 | $8 |
| Methylprednisolone | 17 | $190 | $11 |
| Hydrochlorothiazide | 28 | $178 | $6 |
| Meloxicam | 14 | $136 | $10 |
| Prednisone | 32 | $71 | $2 |
2022: 9 drugs
| Cefdinir | 20 | $514 | $26 |
| Levothyroxine | 12 | $283 | $24 |
| Atorvastatin | 11 | $191 | $17 |
| Pantoprazole | 12 | $162 | $14 |
| Amlodipine Besylate | 14 | $145 | $10 |
| Prednisone | 31 | $131 | $4 |
| Promethazine | 14 | $129 | $9 |
| Hydrochlorothiazide | 13 | $59 | $5 |
| Metformin | 11 | $38 | $3 |
2021: 9 drugs
| Albuterol Sulfate Hfa | 22 | $816 | $37 |
| Doxepin | 11 | $365 | $33 |
| Cefdinir | 14 | $364 | $26 |
| Omeprazole | 11 | $315 | $29 |
| Atorvastatin | 16 | $166 | $10 |
| Amoxicillin-Clavulanate Potass | 11 | $146 | $13 |
| Prednisone | 26 | $111 | $4 |
| Losartan | 13 | $68 | $5 |
| Amlodipine Besylate | 11 | $61 | $6 |
Money from drug and device companies
$214 in 2025
| 2025 | 5 | 11 | None | $214 |
| 2024 | 8 | 12 | None | $248 |
| 2021 | 1 | 1 | None | $12 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Collegium Pharmaceutical | Xtampza | $130 | 7 payments
|
| Abbvie | Botox | $25 | 1 payment
|
| Forte Bio-Pharma | Prolate | $21 | 1 payment
|
| Scilex Pharmaceuticals | Ztlido | $21 | 1 payment
|
| Novo Nordisk | None | $17 | 1 payment
|
See all 11 published payments
| Collegium Pharmaceutical | Meals · 2025-11-19 | Xtampza | $20 |
| Collegium Pharmaceutical | Meals · 2025-08-04 | Xtampza | $16 |
| Forte Bio-Pharma | Meals · 2025-07-31 | Prolate | $21 |
| Collegium Pharmaceutical | Meals · 2025-07-09 | Xtampza | $20 |
| Collegium Pharmaceutical | Meals · 2025-06-09 | Xtampza | $19 |
| Novo Nordisk | Meals · 2025-05-15 | None | $17 |
| Collegium Pharmaceutical | Meals · 2025-03-19 | Xtampza | $19 |
| Scilex Pharmaceuticals | Meals · 2025-02-10 | Ztlido | $21 |
| Collegium Pharmaceutical | Meals · 2025-02-04 | Xtampza | $19 |
| Abbvie | Meals · 2025-02-03 | Botox | $25 |
| Collegium Pharmaceutical | Meals · 2025-01-08 | Xtampza | $18 |
See earlier years (2024, 2021)
2024: $248
| Abbvie | Qulipta | $71 | 3 payments
|
| Scilex Pharmaceuticals | Ztlido | $39 | 2 payments
|
| Collegium Pharmaceutical | Xtampza | $39 | 2 payments
|
| Pacira Pharmaceuticals | Exparel | $27 | 1 payment
|
| Antares Pharma | Xyosted | $22 | 1 payment
|
| Lilly USA | Jardiance | $19 | 1 payment
|
| Amgen | Krystexxa | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $14 | 1 payment
|
2021: $12
| AbbVie | Vraylar | $12 | 1 payment
|
Professional record
- NPI
- 1215496708
- Licence
- AL 1-166647
- Group
- Gardendale Pain and Wellness LLC · Family First Urgent Care Alabama LLC
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X); Federal specialty code 163W00000X (163W00000X)
- Mailing address
- 1802 6th Ave S, Birmingham, AL, 35233
- NPI first listed
- 2019-03-14
- NPI last updated
- 2024-11-12
- NPI record certified
- 2024-11-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1701 Main Ave Sw Ste E, Cullman, AL, 35055 · 3477 Lowery Pkwy Ste 137, Fultondale, AL, 35068